Silence Therapeutics plc
SLNCF
$0.95
$0.451490.53%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 12.20% | -43.47% | 0.01% | 16.57% | -7.00% |
| Total Depreciation and Amortization | -1.26% | -6.54% | -1.44% | -1.12% | 2.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -43.53% | 30.31% | 9.63% | 40.01% | 433.58% |
| Change in Net Operating Assets | -125.74% | 56.70% | 80.21% | -179.91% | -36.35% |
| Cash from Operations | -41.40% | -11.37% | 33.99% | -5.04% | 13.91% |
| Capital Expenditure | -294.29% | -156.57% | -25.06% | 89.50% | 68.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -223.40% | -7,632.64% | 5.02% | -59.88% | 200.10% |
| Cash from Investing | -224.86% | -8,042.03% | 4.92% | -58.29% | 198.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 2.51% | 110.00% | 111.94% | 143.93% | 118.89% |
| Issuance of Common Stock | 333.44% | 709.80% | 195.39% | 222.33% | -36.30% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 834.63% | -788.45% | -- | -- | -- |
| Cash from Financing | 353.49% | 704.52% | 197.10% | 226.26% | -37.30% |
| Foreign Exchange rate Adjustments | -124.03% | -2.25% | 194.97% | 328.70% | 113.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,521.76% | 116.61% | 484.79% | 662.78% | 112.66% |